Drugs / CAR-NK-CD19 Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05563545 | Jul → Nov 2022 | acute lymphoblastic leukemia | Shanghai Simnova Biotechnology Co.,Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04796675 | Apr 2021 → Mar 2023 | B-cell chronic lymphocytic leukemia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-NK-CD19 Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04796675 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor Gene Modified NK Cells Targeting CD19” NCT05563545 ↗ |
| Target | CD19 | “Chimeric Antigen Receptor Gene Modified NK Cells Targeting CD19” NCT05563545 ↗ |